With an executive team unsure how to become more ‘data led’, this project defined, demonstrated then delivered a machine-learning AI to forecast UK drug demand (a disease map) and match stock levels & locations to this. This is a first ‘big data’ project and data layer for the UK division of this large global company. As well as improving the flow of medicines, this unlocked £10's-million of operational efficiencies.
Executive retreat facilitation to develop a five-year Vision and accompanying business plan for continental infrastructure investment, then develop priority business model innovations to accelerate performance.
Opportunities emerged from analysing current corporate reporting, and supporting data assets and governance. The key win was identifying how to use the different ‘currencies’ of sustainability to reposition the company’s customer offer. This aligns doing good with profitable growth.
Post-acquisition integration planning and oversight of a >£1bn purchase led to above expected deal synergies at below expected cost.
This organisation has now moved from the FTSE250 to the FTSE100.
This large higher education organisation had falling student numbers, and revenue.
Redesigning of the end-to-end customer journey targeted
(i) removing obstacles to the current journey, and
(ii) increasing reach to appeal to a wider audience
The results? Increased registrations, impact and revenue.
This FTSE250's Health division was loss-making and unable to release the bandwidth to develop new propositions.
Streamlining roles through a reshaped operating model created capacity. This supported definition of new services and the budget to bring them to market.
Profitable growth has been restored.
Board Advisory Company Limited is a company registered in England and Wales.
© Board Advisory Company Limited